期刊文献+

乳腺癌淋巴结转移与Ki67、VEGF表达的相关性及其临床意义 被引量:13

Correlations between the Lymph Node Status and the Expressions of Ki67,VEGF in the Tissues from Patients with Breast Cancer
下载PDF
导出
摘要 目的探讨乳腺癌淋巴结转移与VEGF(血管内皮生长因子)、Ki67表达的相关关系及其临床意义。方法采用免疫组化法检测125例乳腺癌组织中VEGF、Ki67的表达以及淋巴结转移的情况。结果腋窝淋巴结转移阳性率为72.8%,VEGF、Ki67表达阳性率分别为:56.8%和74.4%,VEGF与Ki67表达呈正相关(P<0.01),淋巴结转移与Ki67表达无显著相关(P>0.05),而与VEGF表达呈正相关(P<0.01)。结论VEGF和Ki67在肿瘤的发生和发展过程中协同作用;Ki67及VEGF的表达与乳腺淋巴结转移是影响乳腺癌预后的重要因素。 Objective To investigate the correlations between the lymph node status and the expressions of VEGF,Ki67 in the tissues from patients with breast cancer. Methods hnmunohistochemical method was used to detect the expression of VEGF and Ki 67 in the tissues from 125 patients with breast carcinoma. Results 72.8% patients had node metastasis. The posi- tive rate of VEGF and Ki67 was 56.8% and 74.4% , respectively. The expression of VEGF was positively correlated to that of Ki67 ;Node metastasis was positively correlated to the expression of VEGF,but not to the expression of Ki67. Conclusion VEGF and Ki67 may be synergically involved in the oneogenesis and development of breast carcinoma. The expressions of VEGF and Ki67, as well as node metastasis are the prognostic factors in patients with breast cancer.
出处 《实用癌症杂志》 2009年第5期450-451,共2页 The Practical Journal of Cancer
关键词 乳腺癌 淋巴结转移 血管内皮生长因子 KI67蛋白 Breast carcinoma Lymph node Vascuoar endothelial cell growth factor(VEGF) Ki67 protein
  • 相关文献

参考文献5

二级参考文献26

  • 1张宏图,胡祥.胃癌病人血清中血管内皮生长因子浓度的临床意义[J].大连医科大学学报,2001,23(2):94-96. 被引量:5
  • 2Pinder SE Wencky P Sibberning DM et al.Assessment of the new proliferation marker MIBI in breast carcinomas using image analysis:association with other prognostic factors and survival.Br J Cancer,1995,71(1):146-149.
  • 3Inden MD,Torres FX,Kubus J,et al. Clinical application of morphologic and immunocytochemical assessments of cell proliferation [J]. Am J Clin Pathol, 1992,97(Suppl 1):4-13.
  • 4Maeda K, Chung Y S, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma[J].Cancer, 1996, 77(5):858-863.
  • 5Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma[J]. Cancer, 2001,92(3): 663-889.
  • 6Poon R T, Fan S T, Wong J. Clinical implications of circulating angiogenie factors in cancer patients[J]. J Clin Oncol, 2001, 19(4):1207-1225.
  • 7Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease[J]. Cancer, 1999, 85(1):178-187.
  • 8Sato K, Tsuchiya N, Sasaki R, et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma[J]. Jpn J Cancer Res, 1999, 90(8):874-879.
  • 9Qian C N, Zhang C Q, Guo X, et al. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma[J]. Cancer, 2000, 88(2):255-261.
  • 10Chin K F, Greenman J, Gardiner E, et al. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer[J]. Br J Cancer, 2000, 83(11):1425-1431.

共引文献35

同被引文献152

引证文献13

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部